Pamidronic acid

From Wikipedia, the free encyclopedia
  (Redirected from Pamidronate)
Jump to: navigation, search
Pamidronic acid
Pamidronic acid.svg
Systematic (IUPAC) name
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
Clinical data
AHFS/Drugs.com International Drug Names
MedlinePlus a601163
Pregnancy cat.
Legal status
Routes Intravenous
Pharmacokinetic data
Bioavailability n/a
Protein binding 54%
Metabolism Nil
Half-life 28 ± 7 hours
Excretion Renal
Identifiers
CAS number 40391-99-9 YesY
ATC code M05BA03
PubChem CID 4674
DrugBank DB00282
ChemSpider 4512 YesY
UNII OYY3447OMC YesY
KEGG D07281 YesY
ChEMBL CHEMBL834 YesY
Chemical data
Formula C3H11NO7P2 
Mol. mass 235.07 g/mol
 YesY (what is this?)  (verify)

Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. It is marketed by Novartis under the brand name Aredia. In India, it is marketed by Curacell Biotech under the brand name Pamimed.

Uses[edit]

It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta, brittle bones and fragile fatigues.

Administration[edit]

Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.

Side effects[edit]

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[1]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.

References[edit]

  1. ^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.